Comparison of Objective Measures of Trismus and Salivation With Patient-reported Outcomes Following Treatment for Head and Neck Cancer

被引:4
作者
Long, Sallie M. [1 ]
Singh, Annu [2 ]
Tin, Amy L. [3 ]
O'Hara, Bridget [2 ,4 ]
Cohen, Marc A. [5 ]
Lee, Nancy [6 ]
Pfister, David G. [7 ]
Hung, Tony [7 ]
Wong, Richard J. [5 ]
Vickers, Andrew J. [3 ]
Estilo, Cherry L. [2 ]
Cracchiolo, Jennifer R. [5 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med, Dept Otolaryngol Head & Neck Surg, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dent Serv, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY USA
[4] CentraState Healthcare Syst, Freehold Township, NJ USA
[5] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA
[7] Mem Sloan Kettering Canc Ctr, Med Oncol, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
QUALITY-OF-LIFE; XEROSTOMIA;
D O I
10.1001/jamaoto.2022.1495
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
IMPORTANCE Xerostomia and reduced mouth opening are negatively associated with quality of life after radiation therapy (RT) for head and neck cancer. Studies comparing objective measures of function with patient-reported outcomes (PROs) have not revealed a clear association. OBJECTIVE To determine how much of the variation in PROs is explained by objective measures of salivary gland and oral cavity functions (salivary flow and maximal interincisal opening). DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study at a single academic cancer center evaluated 112 patients who underwent RT for head and neck cancer between January 2016 and March 2021. Measurements of pre-RT and post-RT saliva and a complete PROs scale within 6 months of the post-RT measurement were analyzed using pairwise associations. INTERVENTIONS Three independently scored PRO scales from the validated FACE-Q Head and Neck Cancer Module were evaluated: eating and drinking, eating distress, and salivation. Three objective measures were analyzed: maximal interincisal opening, stimulated salivary flow, and unstimulated salivary flow. MAIN OUTCOMES AND MEASURES Univariable linear regression models were performed for each PRO against each objective measure, and coefficients of determination (R-2) and 95% Cls were reported. RESULTS The patient cohort comprised 86 men (77%). Median age was 61 years (IQR, 53-68 years), 89 patients (80%) were White, and 61 patients (54%) were current or former smokers. Unstimulated saliva accounted for only a small portion of variation on the salivation scale (R-2 = 14.0%). The remaining associations were even smaller (R-2 = 5.0%10.0%). No upper 95% CI bound included an R-2 of 30%, suggesting that objective measurements do not explain a high level of the variation in PROs. CONCLUSIONS AND RELEVANCE In this cross-sectional study, objective measurements of salivary flow and mouth opening explained only a small fraction of variation in PROs. These findings suggest that factors other than objective function, including patient adaptation, are the dominant influence on PROs in this population. Patient-reported outcomes should be integrated into head and neck cancer clinical care and research. Additional research is required to evaluate which clinicopathological factors influence PROs for salivation, eating and drinking, and eating distress.
引用
收藏
页码:749 / 755
页数:7
相关论文
共 29 条
  • [1] Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Basch, Ethan
    Iasonos, Alexia
    McDonough, Tiffani
    Barz, Allison
    Culkin, Ann
    Kris, Mark G.
    Scher, Howard I.
    Schrag, Deborah
    [J]. LANCET ONCOLOGY, 2006, 7 (11) : 903 - 909
  • [2] The Missing Voice of Patients in Drug-Safety Reporting
    Basch, Ethan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) : 865 - 869
  • [3] Recommended Patient-Reported Core Set of Symptoms to Measure in Head and Neck Cancer Treatment Trials
    Chera, Bhishamjit S.
    Eisbruch, Avraham
    Murphy, Barbara A.
    Ridge, John A.
    Gavin, Patrick
    Reeve, Bryce B.
    Bruner, Deborah Watkins
    Movsas, Benjamin
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (07):
  • [4] Leveraging Patient-Reported Outcomes Data to Inform Oncology Clinical Decision Making: Introducing the FACE-Q Head and Neck Cancer Module
    Cracchiolo, Jennifer R.
    Klassen, Anne F.
    Young-Afat, Danny A.
    Albornoz, Claudia R.
    Cano, Stefan J.
    Patel, Snehal G.
    Pusic, Andrea L.
    Matros, Evan
    [J]. CANCER, 2019, 125 (06) : 863 - 872
  • [5] Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer
    Eisbruch, A
    Kim, HM
    Terrell, JE
    Marsh, LH
    Dawson, LA
    Ship, JA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (03): : 695 - 704
  • [6] Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).
    Ferris, Robert L.
    Flamand, Yael
    Weinstein, Gregory S.
    Li, Shuli
    Quon, Harry
    Mehra, Ranee
    Garcia, Joaquin J.
    Ringash, Jolie
    Lewin, Jan S.
    Duvvuri, Umamaheswar
    O'Malley, Bert W.
    Ozer, Enver
    Thomas, Giovana R.
    Koch, Wayne
    Kupferman, Michael Elliot
    Bell, Richard Bryan
    Saba, Nabil F.
    Lango, Miriam
    Wagner, Lynne I.
    Burtness, Barbara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Ferris RL, 2020, J CLIN ONCOL, V38
  • [8] Patient-reported outcomes in human papillomavirus-related oropharyngeal cancer
    Fitzgerald, Conall W. R.
    Long, Sallie M.
    McLean, Andrew T.
    Cracchiolo, Jennifer R.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2021, 124 (06) : 967 - 976
  • [9] Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
    Gillison, Maura L.
    Trotti, Andy M.
    Harris, Jonathan
    Eisbruch, Avraham
    Harari, Paul M.
    Adelstein, David J.
    Sturgis, Erich M.
    Burtness, Barbara
    Ridge, John A.
    Ringash, Jolie
    Galvin, James
    Yao, Min
    Koyfman, Shlomo A.
    Blakaj, Dukagjin M.
    Razaq, Mohammed A.
    Colevas, A. Dimitrios
    Beitler, Jonathan J.
    Jones, Christopher U.
    Dunlap, Neal E.
    Seaward, Samantha A.
    Spencer, Sharon
    Galloway, Thomas J.
    Phan, Jack
    Dignam, James J.
    Quynh Thu Le
    [J]. LANCET, 2019, 393 (10166) : 40 - 50
  • [10] Hammerlid E, 2001, HEAD NECK-J SCI SPEC, V23, P113, DOI 10.1002/1097-0347(200102)23:2<113::AID-HED1006>3.0.CO